The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Pfizer Inc. /zigman2/quotes/202877789/composite PFE -2.08% recently announced that the United States (U.S.) Food and Drug Administration (FDA) approved CIBINQO(R) (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
"The reality for patients living with chronic inflammatory skin disease such as moderate-to-severe atopic dermatitis is that many experience debilitating symptoms that are not managed by current treatment options. Today's approval of CIBINQO will provide an important new oral option that could help those who have yet to find relief," said Jonathan Silverberg, MD, PhD, MPH, Department of Dermatology, The George Washington University School of Medicine and Health Sciences. "In multiple large-scale clinical trials, CIBINQO demonstrated strong efficacy at clearing skin, improving itch, and managing the extent and severity of eczema, offering a benefit-risk profile that supports the use of this treatment in the FDA-approved patient population."
While this is a clear factor, it has been incorporated into a trading tape characterized by a pretty dominant offer, which hasn't been the type of action PFE shareholders really want to see. In total, over the past five days, shares of the stock have dropped by roughly -5% on above average trading volume. All in all, not a particularly friendly tape, but one that may ultimately present some new opportunities. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -8%.
Pfizer Inc. /zigman2/quotes/202877789/composite PFE -2.08% managed to rope in revenues totaling $24.1B in overall sales during the company's most recently reported quarterly financial data — a figure that represents a rate of top line growth of 98.6%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($29.7B against $41.8B, respectively).
Other key tickers tied to the Covid theme include AstraZeneca PLC ADR /zigman2/quotes/200304487/composite AZN -0.77% , Moderna Inc. /zigman2/quotes/205619834/composite MRNA -1.60% , Merck & Co. Inc. /zigman2/quotes/209956077/composite MRK -2.35% , Johnson & Johnson /zigman2/quotes/201724570/composite JNJ -2.16% , and BioNTech SE ADR /zigman2/quotes/214419716/composite BNTX -3.13% .
Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer . While reading this article one must assume that we may be compensated for posting this content on our website.
The post Covid Stocks Could Represent Huge Value on Sale (NVAX, OTLC, PFE, AZN, MRNA, MRK, JNJ, BNTX) appeared first on Wall Street PR .
Is there a problem with this press release? Contact the source provider Comtex at firstname.lastname@example.org. You can also contact MarketWatch Customer Service via our Customer Center.